These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11314939)

  • 21. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
    Jenkins PJ; Akker S; Chew SL; Besser GM; Monson JP; Grossman AB
    Clin Endocrinol (Oxf); 2000 Dec; 53(6):719-24. PubMed ID: 11155094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
    Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN
    J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome.
    Colao A; Pivonello R; Di Somma C; Tauchmanovà L; Savastano S; Lombardi G
    Clin Endocrinol (Oxf); 2007 May; 66(5):714-22. PubMed ID: 17388794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly.
    Waśko R; Ruchała M; Sawicka J; Kotwicka M; Liebert W; Sowiński J
    J Endocrinol Invest; 2000 Jan; 23(1):12-8. PubMed ID: 10698045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
    Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Somatostatin Analogues in Neuroendocrine Tumors.
    Kulke MH
    J Natl Compr Canc Netw; 2016 Mar; 14(3):241-2. PubMed ID: 26957610
    [No Abstract]   [Full Text] [Related]  

  • 28. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
    Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
    Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.
    Colao A; Auriemma RS; Galdiero M; Lombardi G; Pivonello R
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3746-56. PubMed ID: 19622615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the I.T.M.O. Group. Italian Trials in Medical Oncology.
    Di Leo A; Ferrari L; Bajetta E; Bartoli C; Vicario G; Moglia D; Miceli R; Callegari M; Bono A
    Breast Cancer Res Treat; 1995 Jun; 34(3):237-44. PubMed ID: 7579488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The potential role of somatostatin analogues in breast cancer treatment.
    Pollak M
    Yale J Biol Med; 1997; 70(5-6):535-9. PubMed ID: 9825480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.
    Koutsilieris M; Mitsiades C; Dimopoulos T; Ioannidis A; Ntounis A; Lambou T
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5729-36. PubMed ID: 11739429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study.
    Razzore P; Colao A; Baldelli R; Gaia D; Marzullo P; Ferretti E; Ferone D; Jaffrain-Rea ML; Tamburrano G; Lombardi G; Camanni F; Ciccarelli E
    Clin Endocrinol (Oxf); 1999 Aug; 51(2):159-64. PubMed ID: 10468985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Somatostatin analogs and prednisone in advanced refractory thymic tumors.
    Palmieri G; Montella L; Martignetti A; Muto P; Di Vizio D; De Chiara A; Lastoria S
    Cancer; 2002 Mar; 94(5):1414-20. PubMed ID: 11920496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment.
    Baldelli R; Battista C; Leonetti F; Ghiggi MR; Ribaudo MC; Paoloni A; D'Amico E; Ferretti E; Baratta R; Liuzzi A; Trischitta V; Tamburrano G
    Clin Endocrinol (Oxf); 2003 Oct; 59(4):492-9. PubMed ID: 14510913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.
    Sullivan I; Le Teuff G; Guigay J; Caramella C; Berdelou A; Leboulleux S; Déandréis D; Hadoux J; Ducreux M; Duvillard P; Adam J; Scoazec JY; Baudin E; Planchard D
    Eur J Cancer; 2017 Apr; 75():259-267. PubMed ID: 28242503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
    Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
    J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
    Guadalupe E; Deshpande HA; Stein SM
    Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis.
    Massironi S; Zilli A; Fanetti I; Ciafardini C; Conte D; Peracchi M
    Dig Liver Dis; 2015 Nov; 47(11):978-83. PubMed ID: 26321479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.